Under the agreement, the companies will advance development of IBI3009, Innovent’s ADC candidate, which has received IND approvals in the US, China, and Australia.

The European Commission has approved Novo Holdings' acquisition of Catalent, which includes the related sale of three manufacturing sites to Novo Nordisk, which is also acquiring the Czech Republic ...

It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.

Optimizing Drug Packaging: Strategic Approaches for De-Risking Drug Development ...